| News

500 words on the DayOne Conference 2018

18.09.2018

DayOne has a history of changing and growing each year. This year the DayOne Conference took place on 11 September, and it kept its promise and it felt like several gears were being shifted. This has to do with three factors: world relevance, innovation community engagement and patient dialogue outreach.

DayOne Conference 2018
DayOne Conference 2018 (img: Pino Covino)

First of all, the conference ambition to reach out and connect to innovators world-wide was clearly visible. The world converged at Basel with Africa, Asia, America, Australia and Europe being represented on the podium, and Basel reached out to the world with several “local” initiatives that have the potential to bring about citizen-centricity in health-care (e.g. Oonida). Many common challenges related to access to quality health care are shared world-wide. Though the speakers and panels agreed that digital solutions are not a panacea, they offer opportunities for convergence beyond geography and, through the prism of our differences, we will benefit from mutual learning. Asia may be leading the way in online-based health services, with already 500 million connected users via Tencent, also using European techs (TenCent/ Babylon). African countries may soon be leading the way in early adoption of remote digital diagnostics. DayOne is one of the elements showing that Basel is a good place in the world to connect personalized medicine treatment developments to digital healthcare.

The second point, innovation community engagement, is that DayOne started “walking the talk“ by modelling a collaborative mode within the conference itself. Twenty-three innovators pitched their vision to the participants, who then engaged with them in as many “design-thinking” work groups. This created an engaging environment, breaking down the usual conference barriers and connecting people with diverse expertise. This is crucial since the challenges were as diverse as tough, ranging from juvenile ADHD and autism spectrum strategies to Alzheimer’s, from malaria diagnostics to personalized medicine drug testing and to open-source insurance systems.

The final take-home point, patient dialogue outreach, is probably the most important. The balance of power in healthcare may start to shift towards the patient. DayOne initiated a connection with patients as active participants in the event. Marie Ennis-O’Connor gave a voice to many patients and urged the community to “design for real patients” and engage with them “as human beings”, including “digital empathy”. And to listen, to really listen, to patients.

The starting point of innovation is reality, and our “Day 0” should be the patient.

Find more about the DayOne Conference 2018 here.

Guest article from Giovanni Nisato, edited by Catherine Nisat

DayOne focuses on the patient

The 2018 DayOne Conference – Shaping the Future of Health was held on September 11th at the Congress Centre Basel.

This was the first year as a Patients Included conference that helped to bring a stronger focus on the patient. The morning had excellent keynotes from Patient Expert Marie Ennis O’Connor, Maneesh Juneja and Bram Stieltjes and Andreas Wicki from the University Hospital Basel. These were followed with two monster panels capturing a diverse range of opinions.

The afternoon was given over to group work helping 23 projects to define their superhero story and then a final keynote from Koen Kas and recap on the day.

This year there was also a significant number of volunteer mentors and also a number of willing volunteers who helped make the day run smoothly. DayOne and the BaselArea team would like to thank them for their effort and enthusiasm.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.